CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
|Videos|April 10, 2023
New Podcast Announcement!
Coming soon: the inaugural episode of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care,” with hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA.
Advertisement
Coming soon: the inaugural episode of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care,” with hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA.
Advertisement
Related to this article
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
3
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
4
Consensus Helps Dermatologists Spot CTCL Mimicking Atopic Dermatitis on Dupilumab
5